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Abstract: Resistance to radio and chemotherapy is one of the major drawbacks in the progression of head and neck 
squamous cell cancer (HNSCC) patients, evidencing the importance of fi nding optimum molecular prognosis markers to 
develop personalized treatment schedules. TGF-β effector TAK1 activity has been related to a greater aggressiveness in 
several types of cancer (Kondo et al. 1998; Edlund et al. 2003; Kaur et al. 2005) and, although there has been described no 
signifi cant implication of TAK1 in HNSCC development, we have further examined the role of its mRNA expression as a 
marker of prognosis in HNSCC. Fifty-nine advanced HNSCC patients were recruited for the study. The tumor expression 
of TAK1 mRNA was analyzed with RT-PCR using Taqman technology and its relationship with the clinical outcome of the 
patients studied. TAK1 mRNA expression was lower in patients that relapsed than in those that did not, but the difference 
was only signifi cant between the patients that showed response to treatment (p  0.001). ROC curve analyses pointed a 0.5 
expression ratio TAK1/B2M value as an optimum cut-off point for relapse and response. Our data suggest the TAK1 mRNA 
analysis by Taqman RT-PCR can predict the risk of relapse in HNSCC patients.
Keywords: real-time PCR, prognosis, molecular markers, head and neck cancer, TAK1.
Introduction
Cancers of the head and neck (HNSCC) account for 5% of all cancers detected per year. At least 90% 
are diagnosed as squamous cell carcinomas (Moore et al. 2004). Patients with locally advanced HNSCC 
enclose a bad prognostic group with less than 30% of surviving patients fi ve years since fi nishing treat-
ment, despite the improvements in surgery and new therapeutic approaches. Although clinical progno-
sis factors that determine tumor response to treatment have already been widely studied, less has been 
done in the fi eld of the molecular factors with only several of them having a prognostic value defi ned 
by previous authors (Jayasurya et al. 2004; Smith et al. 2001).
TGF-β signalling pathway involvement in head and neck tumorogenesis through its growth inhibi-
tory effect (Paterson et al. 2001; Prime et al. 2004; Lu et al. 2004; Rosenthal et al. 2004) has been widely 
studied (Prime et al. 2004; Paterson et al. 2001; Rosenthal et al. 2004; Garrigue-Antar et al. 1995; Lu 
et al. 2004; Muro-Cacho et al. 1999; Pasche, 2001). TGF-β-activated kinase 1 (TAK1) was originally 
identifi ed as an MAP-3-kinase activated downstream of TGF-β/BMP receptors, positively regulating 
the SAPK/JNK and p38 kinase pathways (Yamaguchi et al. 1995). Since then, it has been identifi ed as 
an effector in other signaling cascades aside TGF-β (Shim et al. 2005) such as, TNF (Srivastava et al. 
2007), IL-1(Choi et al. 2007) or lymphocyte differentiation (Shim et al. 2005; Delaney and Mlodzik, 
2006). TAK1 activates the inhibition of cyclins D1 and A expression apart from mediating in BMP-2 
inducible apoptosis (Wang et al. 1997). These pathways suppress cell growth in response to stress sig-
nals such as radiation and chemical damage (Singhirunnusorn et al. 2005; Wang et al. 1997). This role 
as tumor suppressor has been previously reported regarding lung cancer (Kondo et al. 1998), prostate 
cancer (Edlund et al. 2003) and liver cancer (Kaur et al. 2005). These studies established that the tumor 
tissue presents low levels of TAK1 expression or activity linked to a greater aggressiveness of disease, 
but there has not been described any signifi cant implication of TAK1 in the development of HNSCC.
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In the present study, we have further examined 
the role of TAK1 mRNA expression as a candidate 
to become a marker of prognosis in HNSCC.
Materials and Methods
Treatment
Fifty nine patients were recruited with AJCC stage 
II, III and IV after anatomopathological diagnosis 
of HNSCC (Table 1). They were enrolled in the 
study with approval from the institutional review 
board and after giving informed consent. Biopsies 
were collected at diagnosis and stored with RNA 
later® (Ambion, Austin, TX) at –80 ºC.
Treatment consisted of preoperative radiotherapy-
acceleration fractionation with concomitant boost 
(72 Gy) and two cycles of concomitant cisplatin 
(20 mg/sqm/day, days 1–5 and 29–33, by continuous 
perfusion). Patients with a creatinine level above 
1.3 mg/ml received carboplatin 60 mg/m2/day in the 
same time. All patients with normal cardiac function 
receive amifostine, 200 mg/m2 intravenously by 
3 minutes infusion, previously to the fi rst fraction 
of irradiation during the treatment course to prevent 
the toxic effects of the treatment. Surgical resection 
was carried out 3–4 weeks after the end of radio-
therapy. After the preoperative treatment, patients 
were re-evaluated with fi berscopy and CT scanning 
following the RECIST guidelines (Husband et al. 
2004). To proceed, patients were required to have 
adequate bone marrow recovery (defi ned as WBC 
count  100000cells/μl). After surgical resection, a 
pathological complete response (CR) was defi ned 
as the absence of residual tumor in the primary 
tumor and lymph nodes.
Response assessment
To evaluate the clinical response to treatment WHO 
bidimensional criterion were followed (Therasse 
et al. 2000; Miller et al. 1981). To simplify the 
clinical data harvesting, stabilised and progressive 
disease were classifi ed as “No Response”, therefore 
Complete and Partial response were classifi ed as 
“Response”.
RNA isolation and cDNA synthesis
Total RNA was isolated from tumor tissue using a 
Trizol® reagent (Invitrogen, Breda, The Nether-
lands)/RNeasy mini columns (Qiagen, Valencia, 
CA, U.S.A.) hybrid protocol; 25 mg of the frozen 
tumoral tissue was dipped in 1.5 ml of Trizol® 
reagent. Tissue samples were homogenized with 
Utra-Turrax homogenizer (Ika®-Werke, Schott 
Ibérica, S.A. Barcelona, Spain) and stored at room 
temperature (RT) for 5 minutes. 150 μl of chloro-
form 100% were added to the homogenate and 
shake vigorously for 15 seconds and then allowed 
to settle at RT for 10 minutes. After centrifugation 
at 12000 g 15 min at 4 °C the aqueous phase (top) 
was transferred to a new tube. Then, 375 μl of 
isopropanol 100% were added to each of the tubes 
and allow to sedimentate at room temperature for 
10 minutes. The isolated RNA was precipitated by 
centrifugation at 12000 g 10 minutes at 4 ºC and 
washed with 1 ml of ethanol 75% and further spin 
at 7500 g during 10 minutes. The RNA was dried 
at room temperature and underwent subsequent 
wash and DNase treatment with the Quiagen 
RNeasy columns according to the manufacturer’s 
protocol. RNA quantity was measured with the 
NanoDrop® ND-1000 UV-Vis Spectrophotometer 
(NanoDrop Technologies), and its quality was 
tested through 2% agarose gel electrophoresis.
To generate complementary DNA (cDNA), total 
RNA was reverse transcribed using 2.5 units/μl 
of murine leukemia virus reverse transcriptase, 
2.5 μM random hexamers, dNTPs (2 mM each) and 
1 unit/μl of RNase inhibitor (Applied Biosystems, 
Rotkreuz, Switzerland). The reverse transcriptase 
reaction was performed in a total volume of 100 μl 
in a GeneAmp polymerase chain reaction cycler 
(Applied Biosystems, Rotkreuz, Switzerland) at 
25 °C for 10 minutes, followed by 30 minutes at 
48 °C and 5 minutes at 95 °C. The cDNA was stored 
at −20 °C until its further analysis.
Housekeeping gene
In order to choose the most appropriate housekeep-
ing gene for the real-time PCR analysis, the assay 
“TaqMan® Human Endogenous Control Plate” 
(Applied Biosystems, Rotkreuz, Switzerland) was 
performed with three randomly chosen samples. 
The most suitable housekeeping gene was β-2-
microglobulin (B2M) (data not shown).
Real time-PCR assays
Real Time-PCR analyses were performed with the 
commercial assays “Assay on the Demand” from 
Applied Biosystems (Rotkreuz, Switzerland). Assay 
number Hs00177373_m1 was employed for the 
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TAK1 mRNA and assay number Hs99999907_m1 
for the housekeeping gene B2M mRNA.
PCR amplifi cations were performed on ABI 
Prism 7700 SDS (Applied Biosystems, Rotkreuz, 
Switzerland). The reactions contained 12.5 μl of 
TaqMan Universal Master Mix (which includes 
amplitaq gold DNA polymerase, dNTP’s with UTP, 
MgCl2, ROX, Amperase UNG and buffers), 1.25 μl 
of each commercial Assay on Demand and 5 μl of 
cDNA template. Reactions were carried out in ABI 
Prism 96-well optical reaction plates with 96-well 
optical covers (Applied Biosystems, Rotkreuz, 
Switzerland) under Universal Cycling Standard 
Conditions (2 min at 50 °C, 10 min at 95 °C and 
40 cycles of 15 s at 95 °C, 1 min at 60 °C). Each 
sample was analyzed three times to obtain two 
replicates of the measure.
Standard curve and amplifi cation 
effi ciency 
A control RNA (Control Human RNA, Applied 
Biosystems, Rotkreuz, Switzerland) was included 
in the study as quality control and as reference to 
perform the expression differences calculations. 
With this RNA a standard curve for each gene, 
including the housekeeping gene, was added in 
each assay. The curves were done in order to 
provide the effi ciency of each reaction (E% = 
(10−1/slope−1)*100), and to deduce the curve equa-
tion that allowed to calculate the relative dilution 
of each gene in each sample. This is a way to 
improve the measurements by normalizing not only 
by the housekeeping gene expression but also by 
the expression levels in the control sample.
Relative expression calculation 
methods
The equation used to calculate the expression ratio 
for each gene in each sample was: Ratio Gene 
X = Relative Dilution gene X/Relative Dilution B2M. 
The obtained data was a relative ratio normalized 
fi rstly against the sample housekeeping gene expres-
sion. Following, it was again normalized by using 
the expression of the housekeeping gene and the gene 
in study (TAK1) in the control mRNA (Fig. 1).
Statistical analysis
SPSS 11.0 software was employed to perform 
statistical analysis. Expression ratio values were 
transformed by logarithm in order to test the nor-
mality distribution. The normality status was 
checked with the Shapiro-Wilk test. The expression 
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Figure 1. Using the control RNA as a “Calibrator Sample”, we built two standard curves or lines, one for the housekeeping gene, B2M, and 
one for the gene in study, TAK1. These standards enabled the control of the effi ciency of the reaction in each experiment performed and, at 
the same time, they served as a third level of normalization for the data obtained from Real Time PCR. In particular, we used them to cal-
culate in each sample the concentration of each mRNA, the housekeeping gene’s and TAK1 gene’s relative to the concentration of these 
mRNAs in the Calibrator sample. Calculating the ratio between these two Relative Concentrations we obtained a dimensionless measure 
directly proportional to the TAK1 mRNA amount expressed in each tissue sample tested. In the example exposed in the fi gure we calculated 
for a sample a relative expression value of TAK1 of 0.59 extrapolating the mean Ct values obtained in the Real Time PCR measurement in 
the standard curves/lines built with consecutive dilutions of the Calibrator mRNA. Once obtained a value of Ln Calibrator relative dilution for 
each gene, we raised e to that value and calculate the dimensionless ratio we were searching.
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of TAK1 was compared among the different 
clinical and pathological variable and response 
patterns by using one-way ANOVA tests and the 
post-hoc tests LSD or Tanhame depending of the 
homogeneity of variance.
The accuracy of the TAK1 expression levels 
measurements in the response to treatment predic-
tion was assessed on the basis of the area under the 
ROC curve (Receiver Operating Characteristic). 
The optimal ROC curve threshold matched the size 
breakpoint showing improved sensitivity and 
specifi city. The area under the curve 0.7 to 0.9 
value indicated moderate accuracy. In addition, the 
sensitivity, specifi city, and positive and negative 
predictive values were calculated for several cutoff 
points obtained from the ROC curve. To assess the 
differential distribution of the patients according 
to the ROC designated cutpoint a Chi Square test 
was performed.
Results
RT-PCR expression measurements
The calculation method applied in this study 
reports the expression levels as non-dimensional 
concentration rates. These concentrations belong 
to the TAK1 gene mRNA and the housekeeping 
gene B2M mRNA analyzed in each sample. 
The control sample allowed building two sepa-
rate standard lines for the target gene, TAK1, 
and the housekeeping gene B2M. Standard lines 
that are employed to extrapolate the results 
obtained for the target gene mRNA and the 
housekeeping gene mRNA. The data obtained 
are relative concentrations to the control sample 
and not real concentrations. Therefore the final 
ratio expresses, in a directly proportional way, 
the target gene mRNA levels that each sample 
contains.
However as the variable “TAK1/B2M expres-
sion ratio” did not follow a normal distribution, 
each value was transformed with neperian loga-
rithm. The transformed variable fi tted a normal 
distribution (PKolmogorov-Smirnov  0.05).
Clinical outcome
The clinical data obtained at the end of the follow-
ing period (Table 2) showed that none of the 
patients included in the study achieved a complete 
response to treatment.
The majority of the patients did not develop 
severe toxicity to radiotherapy, nine patients suf-
fered distant metastasis, most of them located in 
the lungs and within fourteen months since the end 
of the treatment. But almost half of the studied 
patients (45%) suffered from local relapses of the 
disease and the median survival without them was 
of twenty-four and a half months.
The statistical analysis showed no signifi cant 
relationship among the different clinical variables 
considered including clinical data such as tobacco 
consumption or gender (Table 1).
Table 2. Clinical data of the patients included in the 
study at the end of the following period. The Final clini-
cal status is codifi ed as: alive without disease (AWOD), 
alive with disease (AWD), dead without disease (DWOD) 
and dead with disease (DWD). Relapse and metastasis 
free survival medians are expressed in months.
 Patients Total %
Response 59 100
Complete response 0 0
Partial response 17 28.8
Stable disease 42 71.2
Toxicity to radiotherapy
No toxicity 26 44.1
II 20 33.9
III 11 18.6
IV 2 3.4
Final clinical status
AWOD 29 49.2
AWD 15 25.4
DWOD 8 13.6
DWD 7 11.9
Local relapse development
No 32 54.2
Yes 27 45.8
Metastasis development
No 50 84.7
Yes 9 15.3
Metastasis localization
No metastasis 50 84.7
Lung 6 10.2
Bone 1 1.7
Lymph node 5 8.5
Liver 4 6.8
Skin 2 3.4
Median relapse free survival 
(months)  24.5
Median metastasis free survival 
(months)  14.0
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TAK1 mRNA expression levels, 
response to treatment and local 
relapse development
The studied patients showed a different expression 
pattern depending on the achieved response to the 
applied treatment. The interaction analysis showed 
that this differential pattern is modulated by the 
local relapse development (p = 0.02).
According to the statistical analysis, patients 
that developed response to treatment showed 
higher tumoral TAK1 mRNA expression levels 
than those that did not achieve any response. At 
the same time this expression levels were also 
elevated in the tumor tissue of the patients that did 
not develope a local relapse in contrast to those 
that suffered a local relapse.
Among patients that showed response to treat-
ment, those that developed a local disease relapse 
despite the treatment effi ciency had lower tumor 
levels of TAK1 mRNA than those that did not 
relapse (p  0.001). At the same time, when the 
data were analyzed among patients that suffered a 
local relapse, patients that achieved response to 
treatment had higher tumoral levels of TAK1 
mRNA than the patients that did not respond to 
treatment (p  0.01). (Fig. 2)
As the expression differences were highly 
significant ROC curve (Receiver Operating 
Characteristic curve) analysis was applied 
searching for an expression level as cut-off point 
for response to treatment and relapse (Fig. 3).
Both analyzed ROC curves showed similar 
points with maximum specifi city and sensitivity. 
Both pointed that a 0.5 value of expression ratio 
TAK1/B2M as an optimum cut-off point for relapse 
and respond.
Chi square analysis of the relationship between 
response and relapse and a TAK1/B2M expression 
ratio lower or higher than 0.5 revealed that the vast 
majority of the patients that developed response to 
treatment and did not suffer a local disease relapse 
had an expression ratio higher than 0.5 (90.0%), 
while the majority of patients that did not respond 
to treatment or, despite developing some response 
to the treatment, suffered a local relapse had TAK1/
B2M expression ratio levels lower than 0.5 
(response and relapse 85.7%, no response but no 
relapse 81.8% and relapse and no response 71.2%) 
(p  0.05). (Fig. 4)
Discussion
Growth regulatory proteins of the transforming 
growth factor-β family (TGF-β1) are one of the 
few classes of endogenous inhibitors of cell growth. 
Figure 2. Contrast analysis of the interaction RESPONSE-RELAPSE 
regarding TAK1 mRNA tumor expression. In the columns situated in 
the left of the graphic, it can be observed that the expression levels 
difference, between those patients that suffered relapse and those 
that did not, is statistically signifi cant among the patients that achieved 
some response to treatment.
Table 1. Basic clinical data of the patients included in 
the study. Including risk factor tobacco, age of onset, 
gender, and histological data of the tumour tissue biop-
sied at onset.
 Patients Total %
Gender 59 100
Male 49 83.1
Female 10 16.9
Diagnosis medium age (years)  58.9
Tobacco
Yes 44 74.6
No 15 25.4
Daily tobacco
One packet 34 77.3
Two packets 10 22.7
AJCC
II 5 8.5
III 14 23.7
IV 40 67.8
Histologic differentiation grade
Well 13 22.0
Moderate 37 62.7
Poor 9 15.3
No
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Local relapse
Partial response No response
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These cytokines have been implicated in diverse 
phenomena including growth control, cell adhesion 
and motility, production of extracellular matrix 
components, and alteration of cell phenotype 
(Massague, 1998). An important question is how 
cancer cells escape from normal growth regulatory 
mechanisms to become malignant, and further, 
which events favour progression and metastasis. 
Therefore the comprehension of the roles played 
by the implicated molecular factors in that control 
deregulation is essential. At the same time, transla-
tion of these data to the clinical environment can 
improve not just the development of new therapeu-
tical systems, but also the prognosis and subsequent 
treatment schedule of cancer patients.
There are many studies in different types of 
human tumour that have shown that altered 
inhibition of TGF-β1 cell proliferation during 
malignant transformation is due to down-regulation 
of the TGF-β1 receptor system (Derynck et al. 
2001; Hata et al. 1998; Paterson et al. 2001; 
Yamada et al. 2001; Edlund et al. 2003; Lee et al. 
2001; Pasche, 2001). Although the most studied 
downstream pathway of the TGF-β system are the 
SMAD pathways, it has been demonstrated, in cell 
lines, that the specifi c activation of the p38 MAP 
kinase pathway is essential for TGF-β1-induced 
apoptosis (Edlund et al. 2003). The main TGF-β 
activated kinase in this pathway is TAK1 
(Yamaguchi et al. 1995; Wang et al. 1997). Kaur 
et al. (2005) described that hepatic cancer cell lines 
refractory to the TGF-β antitumoral properties have 
lower levels of TAK1 activity (Kaur et al. 2005). 
Edlund et al. (2003) found that negative TAK1 
prostate cancer cell lines had reduced TGF-beta1-
induced phosphorylation of p38 and apoptosis, and 
described how endogenous SMAD7 interacts with 
TAK1 acting as a scaffolding protein in the regula-
tion of p38 (Edlund et al. 2003). Although TAK1 
participates not only in TGF-β signalling but also 
in many other molecular pathways (Delaney and 
Mlodzik, 2006). It responds to a variety of upstream 
signals, including infl ammatory molecules and 
developmental cues, therefore acting as a common 
effector in regulating cellular responses to stress 
signals coming from different molecular sensors.
Figure 3. ROC analysis for the previous contrast results. The curve on the left hand side analyzes the tumour TAK1 mRNA expression from 
the patients with response to treatment searching for a cut point for the presence of relapse; the second curve (right side) analyzes the dif-
ferences in the patients that although relapsed locally showed some response to treatment and those that did not respond. Both curves 
present a high exactitude (Area Under the Curve approximately 0.9) and both curves point to the same TAK1 mRNA expression level in the 
tumour tissue as a cut off point between bad and good prognosis in these patients: a TAK1/B2M expression ratio of 0.5.
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Based on these fi ndings and the described 
signalling mechanism of TAK1 with its down-
stream targets we suggest that TAK1 downregula-
tion can be also implicated in HNSCC genesis 
and clinical development. We have found not just 
that the patients studied showed a relationship 
between reduced TAK1 tumor mRNA expression 
and poor clinical prognosis, but also that a predic-
tive cutoff value can be set. Therefore TAK1 
mRNA expression could be used as a prognosis 
predictive marker in HNSCC patients. In our 
study a relative expression ratio value lower than 
0.5 would distinguish patients with poor response 
and clinical prognosis.
The application of RT-PCR to the clinical 
environment can provide an accurate and fast tool 
to evaluate certain markers’ levels, being one of 
them the TAK1 mRNA tumor levels in HNSCC 
as the present works establishes. Messenger RNA 
levels may not provide information about the 
protein activity, but it does provide information 
about the tumor cell status. An extremely valuable 
information as the average survival rate of 
advanced Head and Neck patients has hardly been 
increased in the past ten years despite the 
improvements in treatment schedules (Hernández, 
2000).
This study, therefore, encourages further inves-
tigation in the mechanisms that regulate TAK1 in 
the particular case of HNSCC. Once established 
that deregulation of the TGF-β signalling pathway 
is implicated in head and neck tumorogenesis 
(Prime et al. 2004; Derynck et al. 2001; Paterson 
et al. 2001; Rosenthal et al. 2004; Wang et al. 
1997; Garrigue-Antar et al. 1995; Lu et al. 2004; 
Muro-Cacho et al. 1999; Pasche, 2001), the par-
ticular mechanisms which TAK1 employs to 
modulate the tumor cell behaviour in the HNSCC 
case have to be uncovered. Our results suggest 
that Head and Neck tumor cells may overcome 
the pro-apoptotic effects of TGF-β signalling 
pathways through a downregulation of TAK1 
activity, and that one mechanism of downregula-
tion of this activity can be the inhibition of TAK1 
mRNA synthesis as we have found its levels 
decreased.
Financial Support
The present work was supported by the Govern-
ment of Navarra grants.
Confl ict of Interest Notifi cation
There are no actual or potential confl icts of interest 
associated to this manuscript.
Acknowledgements
The authors wish to thank, the Otorrinolaringology 
Department and the Oncology Department staff 
for their assistance in sample gathering and clinical 
data recollection and the Biotechnology Laboratory 
of the University Clinic of Navarre for their 
assistance in data collection.
Figure 4. The table shows the patients’ distribution depending on 
their TAK1/B2M expression ratio related to the ROC curves’ desig-
nated cut off point of 0.5. The graphic represents the patient’s distri-
bution according to their response pattern, relapse development 
pattern and the TAK1/B2M expression ratio. It can be observed that 
the former ROC curves have successfully found a TAK1 expression 
ratio that discriminates patients according to their clinical outcome, 
90.0% of the ones with better prognosis, no relapse and response, 
having TAK1 mRNA expression ratios over 0.5, whereas most of the 
patients that present relapse, no response to treatment or both 
express TAK1 mRNA in the tumour tissue at lower levels than this 
designated ROC curve cut off point.
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